---
title: "Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Scenario analyses"
description: "Formulary evidence on Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Scenario analyses. Topics: Scenario and sensitivity analyses recommended for budget impact analysis, Scenario and sensitivity analyses of a published budget impact model, Sensitivity analyses of a published cost-effectiveness model, Scenario and sensitivity analyses of a published cost-per-responder model, and 2 further topics. 6 evidence topics quoted from 8 sources."
canonical: "https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/economics/scenario-analyses"
published: "2026-11-18T10:43:03-05:00"
modified: "2026-11-18T10:43:03-05:00"
---

# Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Scenario analyses

<a id="heading-4.2.6.2"></a>

## 4.2.6.2 Scenario Analyses

<a id="topic-4.2.6.2-1"></a>

### Budget impact model of cretostimogene grenadenorepvec: scenario analyses

No evidence found.

<a id="topic-4.2.6.2-2"></a>

### Scenario and sensitivity analyses recommended for budget impact analysis

> “Sensitivity analysis should be of alternative scenarios chosen from the perspective of the decision maker.”

Source: [Sullivan et al. (2014)](https://pubmed.ncbi.nlm.nih.gov/24438712/)

> “The Task Force recommends that budget impact analyses be generated as a series of scenario analyses in the same manner that sensitivity analyses would be provided for CEAs.”

Source: [Mauskopf et al. (2007)](https://pubmed.ncbi.nlm.nih.gov/17888098/)

<a id="topic-4.2.6.2-3"></a>

### Scenario and sensitivity analyses of a published budget impact model

> “Scenario analyses demonstrated that even examining a broader population including papillary disease-only patients, the budget impact remained modest ($0.0064-$0.0548 PMPM from Years 1–3). Sensitivity analyses confirmed that results were most influenced by uptake rate, drug cost, and target population size.”
> “Due to the smaller size of the target population, the Year 3 budget impact on a PMPM basis was $0.0039, lower than the base-case results.”
> “In Scenario analysis 3, the budget impact was similar to that of the base-case ($0.0080 PMPM in Year 3).”
> “Overall, the results from the DSAs were similar to the base-case analysis and, in Year 3, the budget impact of nadofaragene firadenovec entry ranged from $0.0069 to $0.0100 PMPM.”

Source: [Yang et al. (2026)](https://www.tandfonline.com/doi/full/10.1080/13696998.2026.2630599)

<a id="topic-4.2.6.2-4"></a>

### Sensitivity analyses of a published cost-effectiveness model

> “Gemcitabine/docetaxel lost cost effectiveness compared to RC if the one-year recurrence free survival decreased from 60% to 50.4%, if the one-year progression free survival decreased from 97% to 92.2%, if the upstaging rate with delayed RC was greater than or equal to 36%, or if the three-month gemcitabine/docetaxel costs exceeded $8,808.”
> “One-way sensitivity analysis showed the model was sensitive to cost alone. Nadofaragene became cost effective with a 21% reduction in 3-month cost, while NAI-BCG would require a 67% cost reduction.”
> “In a probabilistic sensitivity analysis with all model parameters varied simultaneously, the most cost-effective strategy remained pembrolizumab (54%), followed by nadofaragene (35%), and NAI-BCG (11%).”

Source: [Myers et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13454959/)

<a id="topic-4.2.6.2-5"></a>

### Scenario and sensitivity analyses of a published cost-per-responder model

> “TAR-200 continued to demonstrate the lowest total cost per patient achieving and sustaining CR for ≥12 months when reinduction with NAI+BCG was incorporated into the analysis, with an estimated cost of $1,897,937.”
> “The probabilistic sensitivity analysis found a cost-per-responder advantage for TAR-200 relative to other FDA-approved treatments across 58-97% of input specifications, depending on the comparator (Figure 5a through Figure 5e).”

Source: [Williams et al. (2026)](https://www.tandfonline.com/doi/full/10.1080/13696998.2026.2651037)

<a id="topic-4.2.6.2-6"></a>

### Scenario analyses in the ICER review

> “In scenario analyses, when the CR of the hypothetical comparator was increased to 20% in the CIS ± Ta/T1 population, the incremental cost-effectiveness ratio for nadofaragene firadenovec and oportuzumab monatox increased to $155,000 and $407,000, respectively.”
> “The model’s base-case assumption of an ineffective (0% CR) hypothetical comparator is likely overly conservative, so the base-case results can be viewed as the most optimistic scenario and should therefore be interpreted with caution.”

Source: [Beinfeld et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10391138/)

<a id="topic-4.2.6.2-7"></a>

### Price reductions required for cost-effectiveness of pembrolizumab

> “A 5.4% reduction in pembrolizumab's price would make it cost-effective.”

Source: [Joshi et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/36529422/)

> “For index patient 2, pembrolizumab required >90% price reduction to be cost-effective (incremental cost-effectiveness ratios $1,073,240/quality-adjusted life year).”

Source: [Wymer et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33347775/)

## Related pages
- [Cretostimogene grenadenorepvec (CG0070): BCG-unresponsive high-risk non-muscle-invasive bladder cancer](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer.md)
- [Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Terms and abbreviations](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/terms-and-abbreviations.md)
- [Cretostimogene grenadenorepvec (CG0070): BCG-unresponsive high-risk non-muscle-invasive bladder cancer](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/executive-summary) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/executive-summary.md)
- [Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Product information and disease description](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/product-information-and-disease-description.md)
- [Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Clinical evidence](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/clinical-evidence.md)
- [Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Economic information and modeling report](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/economics) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/economics.md)
- [Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: References](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/references) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/references.md)
